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Abstract
 
Interleukin (IL)-9 is a pleiotropic cytokine secreted by T helper (Th)2 cells and has been pro-
posed as a candidate gene for asthma and allergy. We have used mice genetically deficient in
IL-9 to determine the role of this cytokine in the pathophysiologic features of the allergic pul-
monary response–airway hyperreactivity (AHR) and eosinophilia. We have demonstrated that
IL-9 is not required for the development of a robust Th2 response to allergen in sensitized
mice. IL-9 knockout mice developed a similar degree of eosinophilic inflammation and AHR
to their wild-type littermates. Goblet cell hyperplasia and immunoglobulin (Ig) E production
were also unaffected by the lack of IL-9. Moreover, levels of bronchoalveolar lavage (BAL) IL-4,
IL-5, and IL-13 were comparable between wild-type and knockout mice. These findings indi-
cate that IL-9 is not obligatory for the development of eosinophilia and AHR, and imply that
other Th2 cytokines can act in a compensatory fashion.
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Introduction
 
The pathophysiological symptoms of allergic asthma are
thought to occur as a result of an inappropriate immune re-
sponse to innocuous proteins or allergens. This immune re-
sponse to allergen is characterized by eosinophilic inflamma-
 
tion of the airways, airway hyperreactivity (AHR)
 
*
 
, and
antigen-specific IgE production. There is growing evi-
dence that the predominant cell type involved in the regu-
lation of this pathophysiology is the Th2 cell, dominated by
expression of IL-4, IL-5, and IL-13. The contribution of
individual cytokines to the development of particular facets
of the allergic response has been the subject of intense in-
vestigation. In particular IL-4 and IL-13 are involved in the
polarization of effector T cells to those of the Th2 pheno-
type. IL-4 is thought to have an important, but not obliga-
tory, role in the regulation of eosinophilia, AHR and mu-
cus production (1). In contrast, blockade of IL-13 signaling
results in an attenuation of these features (2). Moreover,
IL-13 is able to induce AHR and eosinophilia when di-
rectly instilled into the airways of naive mice or if expressed
transgenically in the lung (2, 3). IL-5 appears to be more
specifically involved in the recruitment and survival of
eosinophils, and therefore plays an important part in the
development of pulmonary eosinophilia.
IL-9 is another Th2-derived cytokine thought to play an
important role in the development of asthma. Evidence
from both murine and human studies shows the IL-9 gene
to be located within an area of the chromosome associated
with susceptibility to AHR (4, 5). Moreover, IL-9 protein
expression is strongly associated with the degree of airway
responsiveness and the asthmatic-like phenotype (6). This
has led to the proposition that IL-9 is a susceptibility or risk
factor for asthma. The biological effects of IL-9 are pleio-
tropic, as it acts as a growth factor for mouse T cells (7), a
maturation factor for B cells (8) and a proliferation factor
for mast cells and hematopoietic progenitors (9). In allergy,
the expression of IL-9 and its receptor is increased and this
increase correlates to changes in lung function (10). Eosin-
ophils also synthesize and secrete IL-9 (11) and evidence
suggests that IL-9 may potentiate eosinophil function in
vivo via interactions with IL-5. IL-9 has been found to in-
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crease eosinophil survival, as well as IL-5–mediated differ-
entiation and maturation (12, 13). In another in vitro
study, IL-9 was found to stimulate mucin production in re-
spiratory epithelial cells (14).
Functional evidence for the involvement of IL-9 in the
development of airway inflammation and bronchial hyper-
responsiveness comes from the phenotype of transgenic
mice constructed using a lung specific promoter to overex-
press IL-9 in pulmonary epithelial cells (15). Mice exhib-
ited a striking eosinophil and lymphocyte rich pulmonary
inflammation, lung mast cell hyperplasia, epithelial cell hy-
pertrophy, and subepithelial collagen deposition. Although
mice showed normal baseline airway resistance their re-
sponse to inhaled methacholine was markedly increased
compared with nontransgenic littermates. Moreover, in a
separate study IL-9 transgenic mice were found to display
significantly enhanced eosinophilic airway inflammation,
AHR and serum IgE in response to pulmonary allergen
challenge (16).
Studies where IL-9 is transgenically expressed associate
IL-9 with phenomena pathognomic of allergic airway dis-
ease, however the direct effect of IL-9 deficiency has not
yet been investigated. Mice deficient in the expression of
IL-9 were described recently (17). Interestingly, these mice
did not show the multifocal effects seen in IL-9 transgenic
mice. Indeed, IL-9 was not required for T cell develop-
ment or differentiation, but IL-9 was necessary for both
mast cell and goblet cell hyperplasia in a Th2-driven pul-
monary granuloma model. In the current study, we have
used these deficient mice to determine the role of IL-9 in
the development of pulmonary inflammation and AHR af-
ter allergen challenge.
 
Materials and Methods
 
Mice
 
Mice deficient in IL-9 were generated as described previously
(17). Mice homozygous for the disrupted IL-9 gene were bred
onto a BALB/cJ background backcrossing for six generations. IL-
9
 

 
/
 

 
 mice and their wild-type (WT) littermates were transferred
to Imperial College animal facility at 6–8 wk of age (25–30 
 
g
 
) and
housed for at least 1 wk before use.
 
Induction of Allergic Airway Disease
 
Groups of IL-9–deficient mice and their WT littermates were
sensitized using OVA (Sigma-Aldrich), at a concentration of 0.01
mg/mouse in 0.2 ml alum (Au-Gel-S; Serva Electrophoresis) in-
traperitoneally on days 0 and 12. Control mice received the same
volume of PBS in alum. All groups of mice were challenged daily
with 5% OVA (aerosolized for 20 min) via the airways between
days 19 and 24. Mice were killed by exsanguination under termi-
nal anesthesia at 24 h after OVA administration and the following
parameters analyzed: AHR, inflammation, IgE, and Th2 cytokine
production.
 
AHR
 
Airway responsiveness was measured in mice 24 h after the fi-
nal OVA challenge by recording respiratory pressure curves by
 
whole body plethysmography (Buxco Technologies) in response
to inhaled methacholine (Sigma-Aldrich; UK at concentrations of
3–100 mg/ml for 1 min, as described previously; reference 18).
 
Cell Recovery
 
Airway Lumen.
 
Bronchoalveolar lavage (BAL) was per-
formed as described previously (19). Briefly, the airways of the
mice were lavaged three times with 0.4 ml of PBS via a tracheal
cannula. Bronchoalveolar lavage (BAL) fluid was centrifuged
(700 
 
 
 
g
 
, 5 min at 4
 

 
C), cells were counted then pelleted onto
glass slides by cytocentrifugation (5 
 

 
 10
 
4
 
 cells per slide). Differ-
ential cell counts (original magnification: 40
 

 
; total area 0.5
mm
 
2
 
 per area randomly selected) were performed on Giemsa
(Shandon) stained cytospins. All differential counts were per-
formed blind and in a randomized order at the end of the study.
 
Lung Parenchyma.
 
To disaggregate the cells from the lung tis-
sue, one lobe (100 mg) of lung was incubated (37
 

 
C) for 1 h in
digest reagent: 75 U/ml collagenase (Type D, 50 U/ml DNase;
Boehringer Mannheim; Type 1, 100 U penicillin and 100 mg/ml
streptomycin; Boehringer Mannheim, GIBCO BRL, and Life
Technologies) in 100 ml RPMI 1640 and FCS. The recovered
cells were filtered through a 70 
 

 
m nylon sieve (Falcon, Mara-
thon Lab Supplies) washed twice and resuspended in 1 ml RPMI
1640/FCS. Cytocentrifuge preparations were stained and
counted as for BAL. A proportion of cells were analyzed for T1/
ST2 expression by FACS
 
®
 
 as described previously (20).
 
Histology.
 
Lung sections from the different experimental
groups of mice were prepared and analyzed as described previ-
ously (21). Briefly, lungs were fixed in 10% neutral buffered for-
malin, paraffin embedded, and sections (4 
 

 
m) were stained with
H&E according to standard protocols. A semiquantitative scoring
system was used to grade the size of lung infiltrates, where 
 

 
5
signified a large (
 

 
3 cells deep) widespread infiltrate around the
majority of vessels and bronchioles, and 
 

 
1 signifies a small num-
ber of inflammatory foci. Goblet cells were counted on Periodic
Acid-Schiff (PAS)-stained lung sections using an arbitrary scoring
system, as described previously (2, 17). PAS-stained goblet cells in
airway epithelium were measured double blind using a numerical
scoring system (0 
 

 
 
 
	
 
5% goblet cells; 1 
 

 
 5–25%; 2 
 

 
 25–50%;
3 
 

 
 50–75%; 4 
 

 
 
 

 
75%). The sum of the airway scores from
each lung was divided by the number of airways examined (20–
30 per mouse), and expressed as mucus score in arbitrary units.
 
Cytokine Analysis
 
Cytokines were analyzed in BAL samples and lung tissue ho-
mogenates. Lung tissue (100 mg) was homogenized in 2 ml
HBSS, centrifuged (1,900 rpm, 10 min) and the supernatant col-
lected. Paired antibodies for murine IFN-
 


 
 and IL-4 (BD
PharMingen) IL-5 (Endogen), and eotaxin (R&D Systems) were
used in standardized sandwich ELISAs according to the manufac-
turer’s protocol. Kits to measure IL-13 were purchased from
R&D Systems. 
 
IgE
 
Levels of total IgE were measured in serum by ELISA using
paired antibodies according to the manufacturer’s instructions
(BD PharMingen).
Levels of anti-OVA IgE were measured in serum by ELISA as
described previously (21), and antibody titers were then related to
pooled standards generated in the laboratory and were assigned
the arbitrary values U/ml.
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Data Analysis
 
Data are expressed as mean 
 

 
 SEM. Statistical significance was
accepted when 
 
P 
 
	 
 
0.05 using the Mann Whitney U Test.
 
Results and Discussion
 
IL-9 Deficiency Has No Effects on the Induction AHR.
 
AHR is a cardinal feature of the pulmonary allergic re-
sponse and has been linked with the development of robust
Th2 responses. To determine whether deficiency in IL-9
has a direct effect on development of airway dysfunction,
AHR was measured by whole body plethysmography 24 h
after the final, serial OVA challenge in knockout (KO) and
WT mice. Fig. 1 shows that increasing doses of methacho-
line elicited a similar response in IL-9–deficient mice com-
pared with their WT littermates. There was no difference
in the response to methacholine in unsensitized (alum/
PBS) wild–type mice or IL-9 KO over the dose range stud-
ied. However, both OVA-sensitized WT and IL-9–defi-
cient mice showed significantly enhanced response to
methacholine after allergen challenge, as compared with
the unsensitized control groups.
Previous studies have proposed IL-9 as a candidate gene
for asthma on the basis of qualitative trait locus analysis (5).
Bronchial hyporesponsiveness in C57Bl/6 mice was found
to be associated with greatly reduced IL-9 levels, in com-
parison with higher IL-9 levels in hyperresponsive DBA/2
mice. Moreover, transgenic mice overexpressing IL-9 un-
der the control of a lung specific promoter show increased
bronchial hyperresponsiveness to inhaled methacholine.
These studies led the authors to propose a role for IL-9 in
the development of AHR. However, we have been unable
to determine any effect on the development of AHR after
allergen challenge of IL-9–deficient mice, indicating that
 
IL-9 is not essential for the development of AHR. There
are multiple cytokines that are thought to play key roles in
the regulation of Th2-directed pathophysiology during an
allergic response. In particular, neutralization studies with
inhibitors of IL-13 in vivo have shown that this cytokine is
absolutely required for AHR and mucus production (22)
and have a role in the regulation of eosinophilia (2). In
contrast, IL-4 is thought to be important for the regulation
of eosinophilia, AHR, and mucus production, but is not
obligatory for these processes (23). It is likely that IL-4, IL-
9, and IL-13 cooperate to promote the development of
AHR, however only IL-13 can compensate for a lack in
IL-4 or IL-9.
 
Development of Pulmonary Inflammation in the Absence of
IL-9.
 
Pulmonary inflammation is one of the characteristic
hallmarks of the allergic response to allergen. Leukocytic
infiltrates are found within the airway lumen, as observed
in BAL, and in the lung interstitium as observed in histo-
logical sections. The predominant leukocyte is the eosino-
phil in conjunction with lymphocytes, primarily of the Th2
phenotype. We determined the extent of inflammation in
both compartments of the lung in sensitized WT and IL-9
KO mice after serial OVA challenge. Cell recruitment to
BAL and lung was comparable between WT KO mice
(Fig. 2 A and B). Differential counts revealed that infiltrates
in both strains of mice were composed of mainly eosino-
phils and lymphocytes. However, there was no difference
in either the total leukocyte infiltration of each compart-
Figure 1. Effect of IL-9 deficiency on AHR. AHR was measured 24 h
after the final OVA challenge using a Buxco system where mice were ex-
posed to increasing concentrations of methacholine (3–100 mg/ml). Re-
sults are shown for Penh after allergen challenge in WT mice and IL-9
KO mice either sensitized to alum/PBS or OVA/alum. Values are ex-
pressed as mean  SEM; n  9–13 per group in two separate experiments.
Figure 2. Differential cell counts in BAL (A) and lung tissue digest (B)
from WT mice (white bars) and IL-9 KO mice (black bars). Mice were
killed 24 h after the final OVA challenge. BAL and lung tissue digest cells
were isolated as described in Materials and Methods. Values are expressed
as mean  SEM; n  11–14 per group in two separate experiments. 
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ment or in numbers of any leukocyte subset between IL-9–
deficient and WT mice.
The extent and anatomical location of leukocyte infil-
trates was determined in H&E-stained sections taken from
mice 24 h after the final allergen challenge using a semi-
quantitative scoring system (20). Challenge with OVA in-
duced a widespread peribronchiolar and perivascular in-
flammation, which was primarily eosinophilic. However,
there was no appreciable difference in the degree of tissue
inflammation observed between experimental groups after
allergen challenge, with WT and IL-9 KO mice showing
similar scores (WT: 4.2 
 

 
 0.4; KO: 4.1 
 

 
 0.3) (Fig. 3 A).
Previous studies with transgenic mice have shown that
overexpression of IL-9 induces eosinophilia (15, 16, 24).
However, development of eosinophilic pulmonary granu-
lomas in response to 
 
Schistosoma mansoni
 
 eggs is normal in
IL-9 KO mice (17). Indeed, this latter study argues against
an obligatory role for IL-9 in development of granuloma
formation and eosinophilia in this model.
Although respiratory mucus protects the lower airways
from dehydration and damage, excessive secretion from
hyperplastic goblet cells contributes to the morbidity and
mortality of many respiratory diseases, including asthma
(25). Quantification of goblet cells stained with PAS re-
vealed similar mucus scores in IL-9 KO mice compared
with WT mice (Fig. 3 B). Transgenic expression of IL-9 in
the lung led to the hypothesis that IL-9 was involved in the
generation of mucus producing cells (15, 26). Moreover,
goblet cell hyperplasia was found to be severely impaired in
IL-9–deficient animals after induction with synchronous
primary granulomas (17). Although we found a slight de-
crease in the degree of goblet cell hyperplasia developing in
the absence of IL-9, the effect did not reach statistical sig-
nificance, unlike during the primary granuloma model, and
was evidently not enough to affect development of AHR.
This difference is probably due to the different complexi-
ties of the immunological stimulus used. The primary gran-
uloma model relies on one intravenous challenge of anti-
gen, whereas the OVA model is induced by two peripheral
adjuvant/antigen sensitizations followed by multiple pul-
monary challenges with soluble antigen. Indeed, secondary
challenge in the pulmonary granulomatous response pro-
duces an equivalent induction of goblet cells, even in the
absence of IL-9 (17).
IL-13 has been shown to play an important role in gob-
let cell hyperplasia, since IL-13 neutralization ameliorates
allergy-induced mucus production (2, 22), and direct instil-
lation of IL-13 to the airway promotes an increase in mu-
cus containing epithelial cells. The roles of IL-9 and IL-13
in regulating mucus cell hyperplasia are likely to be interre-
lated. These cytokines can independently regulate mucin
gene expression when directly instilled into the lung or
added to pulmonary epithelial cells in culture (24, 26). It is
conceivable that during a primary response IL-9 is domi-
nant, but IL-13 can compensate after multiple challenges.
Our data indicate that IL-9 contributes to mucus produc-
tion, but IL-13 is probably able to compensate for a defi-
ciency in IL-9.
Figure 3. OVA-induced lung inflammation in
IL-9 KO and WT mice. An assessment of pulmo-
nary inflammation was made by determining the
extent of inflammatory infiltrates in sections stained
with H&E (A) or PAS (B). Stained sections were
scored as described in Materials and Methods, and
scores for individual WT (squares) and KO (circles)
mice are represented. Bars depict means of groups,
n  8–9 per group. Representative photomicro-
graphs of H&E- and PAS-stained lung sections
from WT (i) and KO (ii) OVA-challenged mice are
shown.
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Previous studies determining the role of IL-9 in pulmo-
nary inflammation have reported changes in mast cell num-
bers in conjunction with the changes in goblet cell hy-
perplasia. A decrease in mastocytosis during primary
 
granuloma formation was observed in the absence of IL-9
(17). Mast cells do not feature prominently in the lungs af-
ter allergen challenge in this particular model, and we
could not detect any difference in numbers of mast cells in
lungs of IL-9 KO mice after challenge (data not shown).
Since IL-9 is a Th2-derived cytokine thought to be in-
volved in the promotion of Th2 responses, we deter-
mined whether the recruitment of Th2 cells to the lung
was affected by a lack of IL-9. This was accomplished by
FACS
 
®
 
 staining of cells isolated from digested lung tissue
using an antibody specific for the Th2 marker, T1/ST2
(20). The percentage of T1/ST2 positive CD4 T cells in
alum control mice was low in both types of mice (WT:
0.9 
 

 
 0.2; KO: 0.6 
 

 
 0.2). Allergen challenge of sensi-
tized mice significantly increased the proportion of CD4
cells positive for T1/ST2, and levels were comparable be-
tween WT and IL-9 KO mice (WT: 11.9 
 

 
 1.1; KO:
8.9 
 

 
 1.5). These results indicate that the generation of
Th2 cells and their recruitment to the lung is unaffected
by the absence of IL-9.
 
Effect of IL-9 Deficiency on the Development of Humoral Im-
mune Responses.
 
Elevated levels of IgE have been reported
to be important in the development of an allergic pulmo-
nary response, and evidence suggests that IL-9 can alter the
in vitro differentiation of B cells and enhance Ig production
(27, 8). We measured total IgE and OVA-specific IgE in
sera from KO and WT mice after allergen challenge. Both
groups of mice showed significantly enhanced production
of total and antigen specific IgE after allergen challenge
(Fig. 4). IL-9 deficiency had no significant effect on the
production of total IgE. Levels of OVA-specific IgE were
Figure 4. Effect of IL-9 deficiency on serum IgE levels. Mice were
killed 24 h after the final OVA challenge, bled via cardiac puncture, se-
rum collected, and analyzed by ELISA for total IgE (A) and OVA-specific
IgE (B). Data are expressed as mean  SEM; n  4–13 per group.
Figure 5. Effect of IL-9 deficiency on cy-
tokine production. IL-4 (A), IL-5 (B), IL-13
(C), and eotaxin (D) levels were measured
in BAL fluid (left) and lung homogenate
(right shaded) by ELISA in samples from
WT mice (white bars) and IL-9 KO mice
(black bars) killed 24 h after the final OVA
challenge. Data are expressed as mean 
SEM; n  14 per group for BAL cytokines;
n  five per group for lung cytokines and
*P 	 0.05 in comparison to WT group us-
ing a Mann Whitney U test.
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slightly lower in the absence of IL-9, indicating that the an-
tigen-specific Ig response was perhaps less efficient.
 
Effect of IL-9 on the Production of Inflammatory Cytokines.
 
The immunologic response to pulmonary allergen chal-
lenge is characterized by the secretion of Th2 cytokines
(28). In particular high levels of IL-4, IL-5, and IL-13 and
low levels of IFN-
 


 
 are associated with a Th2-directed re-
sponse to allergen in the lung. We found elevated levels of
BAL IL-4, IL-5, and IL-13 in both WT and KO mice after
allergen challenge (Fig. 5). Although mice deficient in IL-9
seemed to produce more IL-4 in the BAL compared with
WT mice this was not significant (Fig. 5 A). Interestingly,
similar findings were documented after infection of IL-9
KO mice with the parasitic nematode worm 
 
Nippostrongy-
lus brasiliensis
 
. Increased IL-4 production was detected in
restimulated cells from the mesenteric lymph node of IL-9–
deficient mice (17). This reinforces the idea that the net-
work of Th2 cytokines is delicately balanced during an
immune response and that disruption of this balance by a
deficiency in one cytokine results in an increase in one or
more of the other cytokines. Levels of IFN-
 


 
 remained
low in both IL-9 deficient and WT mice after allergen
challenge (data not shown).
IL-9 has been demonstrated previously to induce che-
mokine expression in cultured lung epithelial cell lines or
when expressed transgenically in the lung (24). We deter-
mined expression of the proeosinophilic chemokine eo-
taxin in BAL and lung samples from allergen-challenged
WT and IL-9 KO mice. IL-9 KO mice produced less eo-
taxin in the lavage and lung tissue in comparison with WT
mice, although this effect was only significant in the lung
tissue (Mann Whitney U test, 
 
P 
 
 
 
0.008) (Fig. 5 D). How-
ever, other studies have shown that eotaxin production is
also regulated by other Th2 cytokines such as IL-13 and/or
IL-4 (29, 30). Our data suggest that although IL-9 may be
involved in eosinophil recruitment by regulating chemo-
kines such as eotaxin, IL-9 expression is not obligatory and
other Th2 cytokines such as IL-4 or IL-13 can compensate
for IL-9 deficiency.
Our data indicate that IL-9 does not play an critical role
in the development of allergic eosinophilia and AHR. We
have demonstrated that Th2 cells are able to migrate to the
lungs and elicit Th2-mediated responses to allergen, even
in the absence of IL-9. This study demonstrates the com-
plexity of the Th2 cytokine response and its role in the de-
velopment of pathophysiological features of the allergic re-
sponse. Our results do not reflect the multifocal effect seen
when IL-9 is transgenically overexpressed. However, our
results indicate that studies investigating the relationships
between key Th2 cytokines will be invaluable in addressing
the contribution of individual cytokines to pathophysio-
logic phenomena characteristic of the asthmatic response,
and questions the value of designing novel therapeutic
strategies targeting single cytokines.
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